Followup on Tysabri

The FDA has followed up on its committee's recommendation and decided to allow Tysabri to return to market. For those who just tuned in, Tysabri appears to be an unusually effective MS drug with a rare but nasty side effect--risk of death from a brain infection called PML. This seems like a good thing, but as I argued earlier, it would have been even better to have let people make their own decisions rather than have the FDA make some global cost/benefit decision.